Compliance of an institution-specific alcohol withdrawal protocol with evidence-based practice guidelines.
Moeller
Karen E
KE
Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, Kansas City, Kansas 66160, USA. kmoeller@kumc.edu
Barnes
Brian J
BJ
Stanley
Karen M
KM
Worrall
Cathy L
CL
Lunsford
Shayna L
SL
Simpson
Kit N
KN
Miller
Justin G
JG
Spencer
Anne P
AP
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D000431:Ethanol / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000523:psychology
D000316:Adrenergic alpha-Agonists; D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D000431:Ethanol; D006220:Haloperidol; D003000:Clonidine; D008140:Lorazepam